-
Citi Is More Bullish On Tobacco, Particularly Altria
Monday, December 2, 2019 - 12:15pm | 366Citi upgraded Altria Group Inc. (NYSE: MO) as part of a more bullish general outlook on tobacco companies, but dropped its rating on Philip Morris International Inc. (NYSE: PM). The stocks moved in accordance, with Altria shares up and Philip Morris stock dropping. The Analyst Citi’s Adam...
-
Arista Hit Hard On Q4 Sales Warning: Is Facebook To Blame?
Friday, November 1, 2019 - 12:31pm | 858Arista Networks Inc (NYSE: ANET) shares were plunging to a two-year low after the maker of data center switches issued a downbeat fourth-quarter outlook Thursday. The Analysts MKM Partners analyst Michael Genovese maintained a Neutral rating on Arista and lowered the fair value estimate...
-
Citigroup Names New President And Head Of Global Consumer Banking
Friday, October 25, 2019 - 1:01am | 380Investment bank Citigroup has promoted Jane Fraser as the corporation’s president, its CEO Michael Corbat announced on Thursday. The position, which had been vacant since April after the retirement of company stalwart Jame Forese, is usually understood to be reserved for the next-in-line CEO...
-
Citigroup Upgrades Uber On Higher Revenue Projections
Monday, October 7, 2019 - 11:44am | 303Citigroup upgraded Uber Technologies Inc (NYSE: UBER) Monday, citing the potential for the stock to rise on better third quarter earnings. The Analyst Itay Michaeli upgraded Uber from Neutral to Buy and maintained a $45 price target. The Thesis Second-half revenue for the ridesharing pioneer is...
-
Citi Bullish On AbbVie As Allergan Deal Provides An Earnings Floor
Thursday, September 26, 2019 - 1:46pm | 331AbbVie Inc (NYSE: ABBV) shares are advancing to their highest level since early July following a positive analyst action on the stock. The Analyst Citigroup analyst Andrew Baum upgraded shares of AbbVie from Neutral to Buy with a $90 price target, suggesting roughly 25% upside from current...
-
Sell-Side On Elliott's Suggestions For AT&T: Already Working On It, Impact Likely Limited
Tuesday, September 10, 2019 - 11:48am | 761Sell-side analysts said Tuesday that much of what activist investor Elliott Management is suggesting for AT&T Inc. (NYSE: T) is already being contemplated — but public criticism from the new investor might make the company more aggressive and forthcoming about its plans....
-
Citi: Solid Biosciences Rally Unsupported By Fundamentals
Thursday, August 29, 2019 - 11:38am | 426Following the near 100% rally in shares of Solid Biosciences Inc (NASDAQ: SLDB) in August, one Citigroup analyst said the stock price is diverging from worsening fundamentals. The Analyst Joel Beatty downgraded Solid Biosciences from Neutral to Sell and maintained a $6 price target. The...
-
CB Insights Looks At How US Banks Bet On A Fintech Future
Monday, August 26, 2019 - 1:13pm | 225U.S. banks aim to leverage fintech in the payments, financial markets, data and blockchain spaces. “In 2019 YTD, U.S. banks have participated in 24 equity deals to fintech companies. This follows a record 2018, where U.S. banks backed 45 equity deals to fintech startups -- a 180% increase...
-
Option Trader Betting Juniper Networks Weakness Will Continue
Monday, July 8, 2019 - 1:32pm | 461Juniper Networks, Inc. (NYSE: JNPR) shares are down 5.6% in the past year, but at least one large option trader is betting Juniper’s earnings report expected out later this month won’t save the slumping stock. The Trade On Monday morning, Benzinga Pro subscribers received an option...
-
How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?
Tuesday, June 4, 2019 - 10:53am | 451Mirati Therapeutics Inc (NASDAQ: MRTX)'s shares have been on a tear, advancing over 50 percent since Amgen, Inc. (NASDAQ: AMGN) uploaded an online abstract of its non-small cell lung cancer candidate May 15 to be presented at the ASCO 2019 annual meeting. An analyst at...
-
5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential
Wednesday, May 29, 2019 - 12:24pm | 731The highly volatile biotech stocks present a high-risk-high-reward proposition. Judicious stock picking is essential to ride the superlative rally in some of these stocks in the wake of make-or-break binary events. Here's a brief on a few small-cap biotech stocks Citigroup analyst Yigal...
-
'Compelling Asset': Splunk Analysts Bullish After Software Company's Q1, But Investors Pull Back
Friday, May 24, 2019 - 4:17pm | 922Data analytics company Splunk Inc (NASDAQ: SPLK) reported a beat-and-raise first quarter Thursday. Notwithstanding the solid results, the stock was sharply lower in Friday's session. BTIG analyst Edward Parker told Benzinga Friday that Spunk had a "great quarter," but billings...
-
It's Time to Enter The Vivint Solar Story, Citi Says In Upgrade
Tuesday, May 7, 2019 - 1:30pm | 457Full-service residential solar provider Vivint Solar Inc (NYSE: VSLR)'s shares are now investable, according to Citigroup. The Analyst Praful Mehta upgraded Vivint from Neutral to Buy and doubled the price target from $4.25 to $8.50. The Thesis Larger players like Vivint are...
-
NIO's Lower Share Price Charges Interest In Chinese EV Maker
Thursday, April 4, 2019 - 10:50am | 414The share price of Chinese electric vehicle maker NIO Inc. ADR (NYSE: NIO) has dropped to a level the sell-side likes given expectations for improving sales, leading two analysts to upgrade the stock. The Analysts Bank of America Merrill Lynch analyst Ming-Hsun Lee upgraded Nio from...
-
Citigroup Cuts Mosaic To Neutral, Says Phosphate Supply Outstrips Demand
Friday, March 29, 2019 - 11:41am | 363With the entry of new competitors, phosphate fundamentals have weakened, according to Citigroup. Moves by Mosaic Co (NYSE: MOS) to improve supply dynamics by curtailing capacity are unlikely to result in a significant upturn, the sell-side firm said in a Friday downgrade. The Analyst...